Pharma Focus Asia

Aucta Pharma and Oakrum Pharma Announce Launch of Generic Version of JADENU(R) Sprinkle (Deferasirox Granules)

Tuesday, June 15, 2021

Aucta Pharmaceuticals, Inc. (Aucta) has partnered with Oakrum Pharma, out of St. Louis, Missouri, to announce the U.S. launch of a generic version of JADENU® Sprinkle (Deferasirox Granules) in 90mg, 180mg, and 360mg strengths.

Deferasirox granules had annual sales in the U.S. exceeding $31 million in the aggregate for the 12-month period ending January 2021 according to available data from IQVIATM.

Shoufeng Li, CEO of Aucta Pharmaceuticals stated, "We are excited to bring another Aucta Pharmaceuticals developed product to the U.S. market through this partnership with Oakrum Pharma. Aucta Pharmaceuticals continues to expand its product portfolio in niche generics and branded specialty products and is anticipating additional approvals and launches in the next 12 months."

Marco Polizzi, CEO of Oakrum Pharma, stated, "The investments that we have made in our product development pipeline since starting this business are expected to provide significant contributions to the growth of Oakrum Pharma over the next couple of years. The launch of Deferasirox Granules is the first of several products that we expect to commercialize over the next 12-18 months. A few of these near-term launches are products developed by Aucta Pharmaceuticals."

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024ISPE Singapore Affiliate Conference & Exhibition 2024Rehab Expo 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024